Keith T. Schmidt

TL;DR: Clinical trials are assessing novel diagnostic tools with a combination of different targeted therapeutics while also examining tumor biomarkers that were previously unexplored in a variety of cancer histologies, further shifting the 1 gene–1 drug paradigm toward a more comprehensive, multigene approach.

TL;DR: The use of second-generation androgen receptor antagonists (SG-ARAs) has greatly impacted the treatment of metastatic prostate cancer, providing tolerable and efficacious alternatives to chemotherapy as mentioned in this paper.

TL;DR: In this article, the extent of inherited susceptibility to small cell lung cancer (SCLC), the most lethal type of lung cancer, was assessed by sequenced germline exomes of 87 patients (77 SCLC and 10 extrapulmonary small cell) and found 42 deleterious variants in 35 cancer-predisposition genes among 43.7% of patients.

TL;DR: The use of HVs in the clinical development of oncology drugs is more limited but is nonetheless useful for evaluating clinical pharmacology and establishing an appropriate starting dose for studies in cancer patients.

TL;DR: Curcumin was shown to down-regulate AR expression, limit AR binding to the androgen response element of the prostate specific antigen (PSA) gene, and reduce the expression of PSA in LNCaP cells.